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Abstract 
 
Objectives: Identifying the signalling pathways underlying the pathophysiology of 
schizophrenia is an essential step in the rational development of new antipsychotic 
drugs for this devastating disease. Evidence from genetic, transgenic and post-
mortem studies have strongly supported neuregulin-1 (NRG1)–ErbB4 signalling as a 
schizophrenia susceptibility pathway. NRG1–ErbB4 signalling plays crucial roles in 
regulating neurodevelopment and neurotransmission, with implications for the 
pathophysiology of schizophrenia. Postmortem studies have demonstrated altered 
NRG1–ErbB4 signalling in the brain of schizophrenia patients. Antipsychotic drugs 
have different effects on NRG1–ErbB4 signalling depending on treatment duration. 
Abnormal behaviours relevant to certain features of schizophrenia are displayed in 
NRG1/ErbB4 knockout mice or those with NRG1/ErbB4 over-expression, some of 
these abnormalities can be improved by antipsychotic treatment. NRG1–ErbB4 
signalling has extensive interactions with the GABAergic, glutamatergic and 
dopaminergic neurotransmission systems that are involved in the pathophysiology of 
schizophrenia. These interactions provide a number of targets for the development of 
new antipsychotic drugs. Furthermore, the key interaction points between NRG1–
ErbB4 signalling and other schizophrenia susceptibility genes may also potentially 
provide specific targets for new antipsychotic drugs. In general, identification of these 
targets in NRG1–ErbB4 signalling and interacting pathways will provide unique 
opportunities for the development of new generation antipsychotics with specific 





Schizophrenia is a devastating psychiatric disorder, affecting 1% of the population 
worldwide, and ranks among the top ten causes of disability in developed countries 
(Murray and Lopez 1996). Schizophrenia is clinically characterised by positive 
symptoms (such as hallucinations and delusions), negative symptoms (such as flat or 
blunted affect, poverty of speech, and social withdrawal), and cognitive deficits (such 
as memory deficits, attenuated attention processes, and executive functioning 
impairment) (Austin 2005). Currently, the symptoms of schizophrenia are principally 
controlled by pharmacological treatment, i.e., antipsychotic medications that are 
primarily effective for positive symptoms (Leucht et al. 2009; Vohora 2007). 
However, current antipsychotics have limited efficacy for negative symptoms and 
cognitive deficits, and have some severe side effects (Deng et al. 2010; Vohora 2007). 
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Over the past half century, the discovery and development of antipsychotic drugs 
were largely dependent on the serendipitous observation of the clinical effects of 
some compounds, studies on the underlying mechanisms of drug actions, and 
modifications of previously used drugs for improving efficacy and reducing side 
effects (Lewis and Gonzalez-Burgos 2006). Unfortunately, these approaches are 
largely not derived from an understanding of the disease pathophysiology, particularly 
the aetiology-based molecular pathways of schizophrenia. Although the aetiology and 
pathophysiology of schizophre nia are still not fully understood, evidence from 
genetic, post-mortem and animal studies over the past decade have identified a 
number of susceptibility genes and related pathways for schizophrenia, including 
neuregulin-1 (NRG1), ErbB4 receptor, disrupted-in-schizophrenia-1 (DISC1), 
dysbindin-1, catechol-O-methyl transferase (COMT), and Akt (Jaaro-Peled et al. 2009; 
Karam et al. 2010; Lang et al. 2007). A key question is whether these susceptibility 
genes and their related pathways have therapeutic potential for the treatment of 
schizophrenia. Recent evidence suggests that the NRG1–ErbB4 signalling pathway 
could be a potential target for the development of new generation antipsychotic drugs 
(Hahn 2011; Karam et al. 2010). 
 
The NRG1–ErbB4 signalling pathway is involved in multiple biological functions in 
neurodevelopment, including neuronal migration, glial cell development, axon 
myelination and guidance, dendritic development, and neurotransmitter signalling that 
have been implicated in schizophrenia (Buonanno 2010; Geddes et al. 2011; Mei and 
Xiong 2008; Rico and Marin 2011). In fact, the NRG1 and ErbB4 genes have been 
identified as candidate genes for schizophrenia by many association studies in several 
ethnic groups (Law et al. 2007; Li et al. 2006; Liu et al. 2005; Lu et al. 2010; 
Nicodemus et al. 2010; Petryshen et al. 2005; Shiota et al. 2008; Squassina et al. 2010; 
Stefansson et al. 2003; Williams et al. 2003; Yang et al. 2003); although there are also 
some contradictory reports (Garcia-Barcelo et al. 2011; Ikeda et al. 2008; Ingason et 
al. 2006; Jonsson et al. 2009). The studies in both post-mortem brain tissue and blood 
lymphocytes report altered expression of NRG1 and ErbB4, and their signalling 
activity in schizophrenic patients (Chong et al. 2008; Hahn et al. 2006; Law et al. 
2006; Pan et al. 2011). Studies in transgenic animal models showed that impaired 
NRG1–ErbB4 signalling leads to behavioural abnormalities relevant to certain 
features of schizophrenia and that these behavioural deficits could be improved by 
anti psychotic treatment (Barros et al. 2009; Dejaegere et al. 2008; Kato et al. 2010; 
Pan et al. 2011; Rimer et al. 2005; Savonenko et al. 2008; Stefansson et al. 2002). 
Accumulated evidence shows that aberrant NRG1–ErbB4 signalling may contribute 
to schizophrenia symptoms, particularly positive and cognitive symptoms (Hall et al. 
2006; Kang et al. 2012; Roussos et al. 2011; Shamir et al. 2012; Yokley et al. 2012); 
however, they contribute less to negative symptoms (Rethelyi et al. 2010). In addition, 
various antipsychotics have different effects on NRG1 and ErbB4 expression and 
signalling (Pan et al 2011). Accumulated evidence shows that NRG1–ErbB4 
signalling is closely interacted with several neurotransmitter pathways (glutamatergic, 
GABAergic and dopaminergic pathways) that are crucial in the pathophysiology of 
schizo phrenia and antipsychotic drug efficacy (Buonanno 2010; Lewis and 
Moghaddam 2006; Neddens et al. 2011; Pitcher et al. 2011). Therefore, NRG1–ErbB4 
signalling may provide some important targets for schizophrenia treatment. This 
article will review the evidence regarding the effects of antipsychotics on alterations 
in NRG1–ErbB4 function, and provide insight into the potential of the NRG1–ErbB4 
signalling pathway as a novel target for the discovery of new antipsychotic drugs. 
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2. NRG1­ERBB4  SIGNALLING  AND  ITS  INVOLVEMENT  IN  THE 
PATHOPHYSIOLOGY OF SCHIZOPHRENIA  
 
2.1  The  structures  of  NRG1  proteins  and  the  downstream  signalling 
pathways 
NRG1 is among a family of growth and differentiation factors encoded by four 
individual genes (NRG1-4). The NRG1 gene generates at least 31 isoforms in humans, 
presumably due to multiple promoters and alternative splicing, that can be grouped 
into six types of proteins with different structures and distinct functional properties. 
Most NRG1 isoforms possess an EGF-like domain, located in the membrane-
proximal area of the extracellular part. There are two types of EGF-like domain: α-
type EGF-like domain and β-type EGF-like domain. In the NRG1 types I, II, IV and 
V isoforms, an immunoglobulin (Ig)-like domain connects with the N-terminal 
sequence and the EGF-like domain. However, the type III isoforms contain a 
cysteine-rich domain (CRD) that has an additional transmembrane domain (TMN). 
The N-terminal sequence of NRG1 types III and VI is connected directly to the EGF-
like domain. The EGF-like domain is connected with a C-terminal cytoplasmic tail 
(for review, see Mei and Xiong 2008). Most NRG1 proteins are generated by 
proteolytic processing (ectodomain shedding) of membrane-anchored precursors (pro- 
NRG1s) at the membrane-proximal region that lies on the C-terminal side of the 
extracellular part, which is regulated by three type I transmembrane proteases: tumor 
necrosis factor-α converting enzyme (TACE, also known as ADAM17) (Montero et al. 
2007), β-site of amyloid precursor protein cleaving enzyme (BACE, also known as 
memapsin 2) (Hu et al. 2006; Willem et al. 2006) and meltrin β (also known as 
ADAM19) (Wakatsuki et al. 2004; Yokozeki et al. 2007). Eventually diffusible, 
mature NRG1 proteins are released into the extracellular space (except in the case of 
NRG1 type III) (Falls 2003). The remaining intracellular membrane-bound NRG1 
fragment can be cleaved by Aph1B/C-γ-secretase, generating an intracellular domain 
that can relocate into the nucleus and regulate gene transcription (Bao et al. 2003). 
 
Diffusible NRG1 binds with a family of type I transmembrane receptor tyrosine 
kinases called ErbB proteins, including ErbB2, ErbB3 and ErbB4 (Bublil and Yarden 
2007). The ErbB protein family consists of four members that are EGF receptors 
(EGFR), known as ErbB1, ErbB2, ErbB3 and ErbB4. Upon the stimulation of NRG1, 
ErbB proteins are dimerised to form several types of homodimers (e.g., ErbB4–ErbB4) 
and heterodimers (e.g., ErbB2–ErbB3, ErbB2–ErbB4 and ErbB4-EGFR) (Falls 2003; 
Mei and Xiong 2008). NRG1 does not bind to ErbB1 and ErbB2. EGFR, encoded by 
the ERBB1 gene, cannot bind to NRG1, but forms an activated heterodimer with 
ErbB4. ErbB2, encoded by the ERBB2 gene, also functions as a coreceptor by 
forming heterodimers with ligand-bound ErbBs (Falls 2003; Mei and Xiong 2008). 
The other two ErbB proteins, ErbB3 and ErbB4, can bind to NRG1, in which ErbB4 
homodimers can both interact with NRG1 and become activated by it as a tyrosine 
kinase (Falls 2003; Mei and Xiong 2008). On the other hand, although ErbB3 has 
been previously considered as kinase-inactive (Falls 2003; Yarden and Sliwkowski 
2001), a recent report showed that the ErbB3 kinase domain is competent to bind ATP 
and catalyse autophosphorylation (Shi et al. 2010). Compared to ErbB3 homodimers 
(inactive) or ErbB4 homodimers that signal only weakly, ErbB3/ErbB2 and 
ErbB4/ErbB2 heterodimers contribute to prolonged and enhanced downstream 
signalling (Yarden and Sliwkowski 2001). The ErbB3 and ErbB4 protein are encoded 
by the ERBB3 and ERBB4 genes, among them ERBB4 gene has been considered as a 
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susceptibility gene for schizophrenia (Garcia et al. 2000; Law et al. 2007; Nicodemus 
et al. 2006; Shiota et al. 2008; Silberberg et al. 2006). Although the ERBB3 gene has 
also been considered as a potential schizophrenia candidate gene (Li et al. 2009a), the 
association of the ERBB3 gene with schizophrenia has not been confirmed in several 
studies (Kanazawa et al. 2007; Li et al. 2009b). Therefore, this review will focus on 
NRG1 signalling through the ErbB4 receptor. An ErbB4 protein contains two 
extracellular CRDs, a TMN, an intracellular juxtamembrane (JM) region, a tyrosine 
kinase domain and a C-terminal cytoplasmic tail (CYT) (Mei and Xiong 2008). 
NRG1s with the β-type EGF-like domain have a higher affinity to ErbB receptors 
(especially the ErbB4 receptor) than NRG1s with the α-type EFG-like domain (Jones 
et al. 1999; Tzahar et al. 1994; Wen et al. 1994) and promotes the phosphorylation of 
ErbB receptors 10 times more effectively than NRG1α (Pinkas-Kramarski et al. 1996). 
In addition, a report by Falls (2003) stated that NRG1β isoforms are 10–100 times 
more potent than NRG1α isoforms, and that NRG1α is mostly involved in breast 
development. Therefore, NRG1β isoforms are more likely to be associated with the 
pathophysiology of schizophrenia than NRG1α isoforms. NRG1 stimulus leads to 
dimerisation and kinase activation of the ErbB4 receptor, resulting in autoand trans-
phosphorylation of the intracellular domains, which activates several signalling 
pathways. For example, NRG1-induced stimulation of ErbB4 receptor frequently 
activates the PI3K (phosphatidyl inositol-3-kinase)– Akt–S6K pathway. ErbB4 CYT-
1 contains a PI3K-binding site that binds the p85 subunit of PI3K and activates this 
kinase, which in turn phosphorylates and activates downstream Akt and S6K (Mei 
and Xiong 2008). The PI3K–Akt–S6K pathway mediates NRG1-induced cell survival, 
and neuronal and synaptic development (Junttila et al. 2000; Kainulainen et al. 2000; 
Krivosheya et al. 2008). By acting through the ErbB4-EGFR heterodimer, NRG1 can 
activate Src family kinases, PLCγ, c-Abl and JNK. Furthermore, NRG1 also activates 
the Raf-MAPK (mitogen activate protein kinase) pathway (Mei and Xiong 2008). 
 
2.2  Pathological alterations of NRG1­ErbB4  signalling  in  schizophrenia 
patients  
Both post-mortem studies and behavioural studies in animal models have suggested 
abnormalities of the NRG1–ErbB4 pathway in schizophrenia (Pan et al. 2011). 
Several postmortem studies have found an increase in the mRNA expression of NRG1 
type I in the prefrontal cortex (PFC) (Hashimoto et al. 2004) and the hippocampus 
(Law et al. 2006); moreover, an increase of the protein level of the NRG1 intracellular 
part in the PFC has also been reported (Chong et al. 2008). However, Hashimoto et al. 
(2004) have shown a decrease in the ratios of type II/I and type II/III mRNA 
expressions (i.e., a relatively decreased expression of NRG1 type II) (Hashimoto et al. 
2004). A study in elderly individuals with schizophrenia has indicated an increased 
NRG1 type II expression but decreased NRG1 type I expression in the PFC 
(Brodmann area [BA] 10) (Parlapani et al. 2010). Additionally, Bertram and 
colleagues (2007) have found using immunohistochemistry and Western blot analysis 
that the NRG1α isoform is decreased in the white and grey matter of the PFC 
(Bertram et al. 2007). Barakat et al. (2010) reported that the full-length type III NRG1 
precursor did not differ between individuals with schizophrenia and healthy controls, 
but the levels of NRG1 type III C-terminal fragment significantly decreased in the 
BA6 of schizophrenia patients (Barakat et al. 2010). Abnormal expression of NRG1 
has also been reported in the periphery, although the results were not consistent. For 
example, the expression levels of NRG1 transcript variants in type I and type III 
isoforms were significantly increased in peripheral blood lymphocytes (PBLs) in 
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schizophrenia (Petryshen et al. 2005), whereas a decrease in NRG1 mRNA expression 
in PBLs and serum NRG1 immunoreactivity were reported by other studies (Shibuya 
et al. 2010; Zhang et al. 2008, 2011). Decreased peripheral NRG1 mRNA in PBLs has 
been found in high-risk individuals who later developed psychosis (Kiss et al. 2012). 
However, a recent study reported no difference in expression of NRG1 mRNA in 
immortalized lymphocytes between schizophrenia and control subjects (Yamamori et 
al. 2011). It is worth noting that treatment with the antipsychotics risperidone and 
quetiapine has been reported to increase NRG1 mRNA expression in PBLs in first-
onset schizophrenia patients (Zhang et al. 2008, 2011). 
 
ErbB4 receptor expression has also been shown to be abnormal in post-mortem brain 
studies. Increases in the protein expression of both the full-length ErbB4 receptor and 
the isoforms containing CYT-1 domain have been reported in the PFC of 
schizophrenia patients (Chong et al. 2008; Silberberg et al. 2006). In addition, the 
mRNA expression of isoforms containing CYT-1 domain and a JM-a domain was 
also increased in the dorsal PFC of schizophrenia patients (Law et al. 2007). Hahn et 
al. (2006) found that, although the expression of both NRG1 and ErbB4 receptors was 
not significantly changed in the PFC of schizophrenia subjects, a marked increase in 
NRG1-induced activation of the ErbB4 receptor and activity of its downstream 
signalling components were observed in patients with schizophrenia (Hahn et al. 
2006). Although the results are not completely consistent, the majority of studies 
demonstrate elevated NRG1–ErbB4 signalling in the brain of individuals with 
schizophrenia (Pan et al. 2011). Furthermore, whether there are developmental 
differences in NRG1–ErbB4 signalling in patients with psychotic symptoms has not 
been investigated. 
 
In brief, while not completely consistent, current data from studies in post-mortem 
brain tissue and PBLs have demonstrated altered NRG1–ErbB4 signalling in 
schizophrenia. It is worth noting that there are a number of limitations to these studies. 
Firstly, many reports focused on relative mRNA levels without attempting to address 
the possible biological significance of the observed difference. For example, what 
might be the biological relevance of the minor changes in the expression of NRG1 
type I and ErbB4 reported previously (Chong et al. 2008; Hashimoto et al.2004)? 
How might isoform-specific changes in expression affect function that could lead to 
pathophysiological changes associated with schizophrenia? Recently, Liu et al. (2011) 
reported the expression of specific NRG1 isoforms in the human and rat post-mortem 
brain with quantitative data in copies/μg total RNA in addition to normalization of 
mRNA levels to β-actin (Liu et al. 2011). This provides an important way to further 
quantitatively analyse of specific NRG1 isoform expression as well as to compare 
relative ratios to housekeeping genes in schizophrenia postmortem studies. In addition, 
there are also problems in specificity of antibodies against specific NRG1 isoforms 
and ErbB4 receptors in terms of interpretation of protein expression in post-mortem 
tissue (Bare et al. 2011; Fazzari et al. 2010; Vullhorst et al. 2009). Therefore, future 
postmortem studies using better quality controlled reagents and quantitative measures 
are required in order to interpret the results and reveal how NRG1–ErbB4 signalling 





2.3  Evidence  from  studies  of  transgenetic  models  with  NRG1/ErbB4 
knock­out and overexpression relevant to schizophrenia  
Along with the findings from post-mortem studies, animals with abnormal NRG1–
ErbB4 functioning display behavioural deficits that resemble the symptoms of 
schizophrenia, including hyperactivity in the novel open-field test and the alternating-
Y maze (Barros et al. 2009; Chesworth et al. 2012; Duffy et al. 2008, 2010; Gerlai et 
al. 2000; Karl et al. 2007; Kato et al. 2010; O'Tuathaigh et al. 2007; Rimer et al. 2005; 
Stefansson et al. 2002; van den Buuse et al. 2009), deficits in prepulse inhibition (PPI) 
level (Barros et al. 2009; Chen et al. 2008; Deakin et al. 2009; Dejaegere et al. 2008; 
Hong et al. 2008; Kato et al. 2010; Savonenko et al. 2008; Stefansson et al. 2002; van 
den Buuse et al. 2009), and lateral inhibition (Rimer et al. 2005), as well as impaired 
social activity (Kato et al. 2010; O'Tuathaigh et al. 2007). These transgenic animal 
models have targeted mutiple mutations in NRG1 genes and the proteolytic 
processing and cleavage of NRG1 proteins, including mutation or deletion of the Ig-
like domain (Rimer et al. 2005), TMN domain (NrgTM) (Chesworth et al. 2012; Karl 
et al. 2007; O'Tuathaigh et al. 2007; Stefansson et al. 2002), type I (Deakin et al. 2009) 
and type III of NRG1 (Chen et al. 2008), Aph1B/C-γ-secretase (Dejaegere et al. 2008), 
and BACE1 (Savonenko et al. 2008). It is worth noting that animals with either 
reduced (O'Tuathaigh et al. 2010; van den Buuse et al. 2009) or excessive expression 
(Deakin et al. 2009; Kato et al. 2010) of the NRG1 gene showed similar behavioural 
deficits. Recently, a knock-out mouse model with ErbB4 ablation specifically in the 
parvalbumin (PV)positive interneurones (PV-ErbB4−/−) was reported to exhibit 
schizophrenia-relevant phenotypes similar to those observed in NRG1 or ErbB4-null 
mutant mice (Chen et al. 2010a; Wen et al. 2010). Together, these studies support the 
hypothesis that abnormal NRG1–ErbB4 signalling is a potential factor for the 
behavioural phenotypes of schizophrenia. Moreover, in these models, behavioural 
phenotypes induced by altered NRG1–ErbB4 signalling are different depending on 
the mutant domains of proteins, age and gender of animals, and the biological context 
of the dysregulation (Desbonnet et al. 2009). For example, male NrgTM mice 
displayed stronger behavioural deficits than female mutants in decreased response to 
the locomotor-activating effects of acute PCP treatment (O'Tuathaigh et al. 2010), in 
social withdrawal-like effects of Δ9-tetrahydrocannabinol treatment (Long et al. 
2010a,b), and in fear conditioning and recognition of a previously encountered object 
(Chesworth et al. 2012; Duffy et al. 2010). Sex-specific phenotypic effects were also 
observed in exploratory and habituation behaviours: female NrgTM mice showed an 
increase in walkovers and shifting of cage bedding, while male mutants exhibited 
reduced grooming (O'Tuathaigh et al. 2006, 2008). On the other hand, hypomorphic 
type II NRG1 (NrgTn) male rats failed to habituate to an open field, while female 
NrgTn rats exhibited reduced locomotor activity and enhanced habituation to a novel 
environment; and only female NrgTn rats had impaired PPI (Taylor et al. 2011). 
Therefore, these results imply that specific personalised treatment may be developed 
according to the different biological status of patients, although it also implies that the 





3. INTERACTIONS  BETWEEN  NRG1­ERBB4  SIGNALLING  AND 





It has been largely accepted that schizophrenia arises as a consequence of abnormal 
brain development (Fatemi and Folsom 2009; Jaaro-Peled et al. 2009). NRG1 and 
ErbB4 are highly expressed in the developing brain (Buonanno 2010; Liu et al. 2011). 
NRG1 transcripts in the brain are expressed at their highest during embryonic, fetal 
and early postnatal periods, and expression decreases with age (Buonanno 2010). 
Considerable evidence has indicated that NRG1–ErbB4 signalling plays critical roles 
in developmental processes, such as radial glia formation and neuronal migration 
(Anton et al. 1997; Rio et al. 1997; Yau et al. 2003), glial cell development, axon 
myelination and axon ensheathment (Calaora et al. 2001; Canoll et al. 1996; 
Michailov et al. 2004; Nave and Salzer 2006; Schmucker et al. 2003; Taveggia et al. 
2005), axon guidance (Bermingham-McDonogh et al. 1996; Gerecke et al. 2004; 
Lopez-Bendito et al. 2006; Rieff et al. 1999), and dendritic development (Chen et al. 
2010b; Gerecke et al. 2004; Rieff and Corfas 2006). NRG1 also affects the 
development of the dopaminergic system and GABAergic interneurones (Balu and 
Coyle 2011; Fazzari et al. 2010; Rico and Marin 2011; Roy et al. 2007). For example, 
peripheral NRG1 administration in neonatal mice activates midbrain ErbB4 receptors 
and elevates the expression, phosphorylation and activity of tyrosine hydroxylase 
(TH). This results increases in the level of dopamine and dopamine release, and 
induces a persistent hyper-dopaminergic state and behavioural impairments in 
prepulse inhibition, latent inhibition, social behaviours and hypersensitivity to 
methamphetamine (Kato et al. 2011). NRG1–ErbB4 signalling is critical for the 
development of inhibitory circuitries and the wiring of GABA-mediated circuits in the 
postnatal cerebral cortex (Fazzari et al. 2010). Therefore, this evidence further 
supports the involvement of impaired NRG1–ErbB4 signalling in the development of 
schizophrenia. 
  
3.2  Effects  of  NRG1­ErbB4  signalling  on  synaptic  plasticity  and 
neurotransmission in the adult brain in relation to schizophrenia 
3.2.1  Interaction  between  NRG1­ErbB4  signalling  and  dopaminergic 
neurotransmission 
Dopaminergic dysfunction is one of the most widely accepted neurochemical 
hypotheses of schizophrenia. It postulates that excess dopaminergic transmission in 
the mesolimbic and striatal regions, and dopaminergic deficits in prefrontal regions, 
are responsible for the positive symptoms and negative symptoms of schizophrenia, 
respectively (Lang et al. 2007). Similarly, Kwon et al. (2008) found that intracerebral 
infusion of NRG1β into the hippocampus increased extracellular dopamine levels 
(Kwon et al. 2008). Direct intracerebral infusion of NRG1β into the substantia nigra 
(SN) evokes an almost immediate overflow of striatal dopamine (Yurek et al. 2004). 
Since ErbB4 receptors are mainly expressed on the dopamine neurons in the SN, these 
results suggested that NRG1 can directly modulate the activity of mesostriatal 
dopaminergic neurons (Abe et al. 2009; Zheng et al. 2009). Carlsson et al. (2011) 
found that dopamine levels increased in the SN and the striatum of adult mice after 
systemic administration of NRG1β (Carlsson et al. 2011). Together, these studies 
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consistently demonstrate that promoted NRG1 signalling is capable of increasing TH 
levels and dopamine release, enhancing dopaminergic neurotransmission. 
 
3.2.2  Interactions  between  NRG1­ErbB4  signalling  and  glutamatergic 
neurotransmission 
considerable amount of research has demonstrated that the ionotropic glutamate 
receptor N-methyl-D-aspartate (NMDA) plays a critical role in the pathogenesis of 
schizophrenia, and that hypofunction of NMDA receptors is a major mechanism 
underlying the pathophysiology of schizophrenia (Kantrowitz and Javitt 2010; Lewis 
and Gonzalez-Burgos 2006). NMDA receptors are composed of a heterometric 
assembly of subunits (NR1, NR2 and NR3), where the NR2 subunit shares a common 
anchoring protein in the post synaptic density (PSD) with the ErbB4 receptor (Chen et 
al. 2006; Cousins et al. 2009; Geddes et al. 2011). Accumulated evidence supports 
that NRG1–ErbB4 signalling is capable of regulating the function of the NMDA 
receptor through the NR2/PSD/ErbB4 complex. For example, MK-801 binding is 
decreased in the PFC of mice with NRG1 EGF-domain mutation, implying reduced 
expression of NMDA receptors (Stefansson et al. 2002). Gu and colleagues (2005) 
reported that NMDA receptor currents and channel activity were significantly 
decreased in the PFC after perfusion of NRG1, suggesting that elevated NRG1 
signalling compromises NMDA function (Gu et al. 2005). Additionally, decreased 
NR2C expression was found in individuals with schizophrenia that had an NRG1 
polymorphism, suggesting deficits in NMDA receptor function (Schmitt et al. 2010). 
Hahn et al. (2006) have found that increased NRG1–ErbB4 signalling (enhanced 
association of ErbB4 receptors with both PSD-95 and the NR1 subunits) was 
associated with suppressed NMDA receptor activation (reduced phosphorylation of 
NR2A subunits) in schizophrenia (Fig. 1) (Hahn et al. 2006). It has also been reported 
that the activation of Src kinases enhances NMDA receptor channel activity and 
mediates the phosphorylation of NMDA subunits (Yu et al. 1997). This Src-mediated 
enhancement of synaptic NMDA function could be suppressed by NRG1–ErbB4 
signalling through PSD-95, causing hypofunction of NMDA receptors in pyramidal 
neurons in the PFC and hippocampus under a preparation of blocked GABA 
neurotransmission; and NRG1–ErbB4 signalling prevents the theta burst-induced 
phosphorylation of NR2B by inhibiting Src kinase activity (Pitcher et al. 2011). On 
the other hand, through activation of Fyn and Pyk2 kinases, NRG1–ErbB4 signalling 
can stimulate phosphorylation of the NR2B subunit of the NMDA receptors 
(Bjarnadottir et al. 2007). 
 
3.2.3  Interaction  between  NRG1­ErbB4  signalling  and  GABAergic 
neurotransmission  
Accumulated evidence supports the contribution of abnormal GABAergic 
neurotransmission in the pathophysiology of schizophrenia (Benes 2009; Deng and 
Huang 2006; Lewis and Gonzalez-Burgos 2006). NRG1–ErbB4 signalling plays a 
critical role in GABAergic interneuron plasticity and transmission. For example, Chen 
et al. (2010a) found that NRG1 increased GABAA receptor-mediated synaptic 
currents in CA1 pyramidal cells. NRG1 also increases evoked release of GABA in the 
PFC by directly activating ErbB4 receptors on presynaptic terminals (Woo et al. 
2007). Moreover, impaired NRG1–ErbB4 signalling may induce a reduction of 
GABA release, resulting in abnormal synchronisation of pyramidal cells, which is 
related to deficits in working memory in schizophrenia (Lewis and Moghaddam 2006). 
Another study found that NRG1 increases the function of GABAergic interneurons in 
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vitro by promoting the frequency and amplitude of miniature excitatory postsynaptic 
currents (mEPSCs), which supports the in vivo finding that mice with deletion of 
ErbB4 receptors in parvalbumin-positive interneurons displayed reduced frequency 
and amplitude of mEPSCs in interneurones (Ting et al. 2011). 
 
3.3  A key role for NRG1­ErbB4 signalling in integrating dopamine, GABA 
and  glutamate  neurotransmission  in  relation  to  the  pathophysiology  of 
schizophrenia 
Given that dopamine, GABA and glutamate systems are responsible for the 
pathophysiology of schizophrenia and are regulated by NRG1–ErbB4 signalling, a 
key question is whether NRG1–ErbB4 signalling plays a crucial role in integrating 
these systems? Also, how does this integrative role contribute to the pathophysiology 
of schizophrenia? A critical step towards addressing these questions is to identify the 
precise locations of ErbB4 receptors. A role for NRG1– ErbB4 signalling in 
glutamatergic transmission between pyramidal cells in the cortex and hippocampus 
was previously assumed (Barros et al. 2009; Bjarnadottir et al. 2007; Kwon et al. 
2005; Mei and Xiong 2008). However, these reports were based on the discovery of 
ErbB4 expression in pyramidal neurons in the cortex using in situ hybridisation and 
immunohistological methods with low-specificity antibodies (Bernstein et al. 2006; 
Thompson et al. 2007), as well as an association between ErbB4 and PSD-95 (Garcia 
et al. 2000; Huang et al. 2000). A study using whole-cell recording in slice 
preparations found that NRG1β suppresses Src-mediated EPSP in the pyramidal 
neurons of mouse hippocampus and prefrontal cortex with blocked GABA 
neurotransmission, and this effect was not observed in ErbB4 mutant mice 
(Erbb4−/−HER4heart). This suggested that ErbB4 receptors are required for 
suppression of Src-mediated EPSP in the pyramidal neurons by NRG1β in this 
experiment (Pitcher et al. 2011). However, other studies using single cell analysis of 
electrophysiologically characterised neurons combined with high-specificity 
antibodies have provided evidence of a lack of ErbB4 expression in any pyramidal 
cells in the cortex and hippocampus (Fazzari et al. 2010; Neddens and Buonanno 
2010; Neddens et al. 2011). Instead, ErbB4 receptors are expressed predominately on 
the GABA interneurons in the frontal cortex (Neddens et al. 2011), primarily (>98% 
in the cortex) on the PV-positive interneurons, including basket and chandelier cells 
that innervate the somata and the axon initial segment of pyramidal cells, respectively 
(Fig. 1). Small numbers of ErbB4 receptors are expressed on calbindin-positive 
interneurons that innervate the dendritic region of pyramidal cells (Fazzari et al. 2010; 
Neddens et al. 2011). According to Neddens et al. (2011), ErbB4 receptors were not 
detected at the presynapses in any GABA interneurons but are highly expressed 
postsynaptically at glutamatergic synapses, where it binds to PSD-95 in GABAergic 
interneurons (Fig. 1). These postsynaptic ErbB4 receptors regulate the formation 
and/or maintenance of excitatory synapses onto GABAergic interneurons and 
neuronal network activity (Cooper and Koleske 2011; Fazzari et al. 2010; Neddens et 
al. 2011). In fact, recent studies have clearly shown that NRG1 regulates pyramidal 
neuron activity and long-term potentiation (LTP) completely via ErbB4 in PV-
positive interneurons in the frontal cortex and hippocampus (Chen et al. 2010a; Wen 
et al. 2010). It is worthy of note that ErbB4 expression is significantly higher in the 
ventral than the dorsal hippocampus of mice (Neddens and Buonanno 2010). 
Consistently, NGR1 type III hypomorphic mice display disrupted activity in ventral 
hippocampal-accumbens transmission (Nason et al. 2011), and subchronic peripheral 
NRG1 treatment selectively increases neurogenesis in the ventral hippocampus 
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(Mahar et al. 2011). In consideration of the fact that neonatal ventral hippocampus 
lesions are a well-recognised model of schizophrenia (Lipska et al. 2003; Tseng et al. 
2009), NRG1–ErbB4 signalling may interact with pyramidal cells and GABA 
interneurons predominately through the ventral hippocampus. Furthermore, the 
predominant location of ErbB4 receptors on PV-positive GABA interneurons in the 
cortex and hippocampus is conserved across species from rodents to primates 
including humans, which supports the relevance of rodents as an appropriate model to 
study the mechanisms of NRG1–ErbB4 signalling in the pathophysiology of 
schizophrenia (Cooper and Koleske 2011; Neddens et al. 2011). 
 
NRG1 elicits a prolonged release of dopamine in the adult hippocampus, which in 
turn suppresses or reverses LTP at hippocampal glutamatergic synapses (Kwon et al. 
2008). Conversely, blockade of ErbB receptors produces a small but significant 
decrease in dopamine release in the dorsal hippocampus of rats (Neddens et al. 2009). 
Therefore, NRG1 may regulate hippocampal dopamine release by acting at ErbB4 
receptors on dopamine terminals. However, since ErbB4 receptors are primarily 
expressed on GABAergic interneurons in the hippocampus (as discussed above), it is 
likely that NRG1-induced dopamine release may be through the action of GABAergic 
interneurons (Balu and Coyle 2011; Kwon et al. 2008). Since both the cortex and 
hippocampus are innervated by dopaminergic fibres from the ventral tegmental area 
(VTA), an alternative mechanism is that NRG1 may regulate dopamine release in the 
cortex and hippocampus by modulating VTA dopamine neurons. In fact, ErbB4 
receptors are located in VTA and SN dopamine neurons of monkeys and humans 
(Thompson et al. 2007; Zheng et al. 2009). A recent study in rats reported that 66–78% 
of cells expressing mRNA for ErbB4 are positive for TH in the VTA and SN pars 
lateralis, and an even higher (94–96%) number of neurons in the SN pars compacta 
coexpress ErbB4 mRNA and TH (Abe et al. 2009). However, ErbB4 mRNA 
reportedly does not colocalise with PV immunoreactivity in both the VTA and SN 
(Abe et al. 2009). These results suggest that NRG1–ErbB4 signalling in the midbrain 
may regulate the activity of excitatory glutamatergic synapses onto dopaminergic 
neurons directly, but not through PV-positive interneurones (Fig. 1). Further studies 
are required to examine whether NRG1–ErbB4 signalling regulates midbrain 
dopamine neurons through other types of GABA interneurons, and whether it 
regulates midbrain dopamine neurons through other brain regions. 
 
The evidence discussed above supports the integral role for NRG1–ErbB4 signalling 
in glutamatergic, GABAergic and dopaminergic neurotransmission; the question is 
how this signalling pathway contributes to the pathophysiology of schizophrenia? 
Recently, NRG1–ErbB4 signalling was reported to suppress Src-mediated increase of 
synaptic NMDA transmission (Pitcher et al. 2011). In view of the fact that NRG1–
ErbB4 signalling is altered in the brain of schizophrenic patients (Bertram et al. 2007; 
Chong et al. 2008; Hahn et al. 2006; Hashimoto et al. 2004; Law et al. 2006; Pan et al. 
2011), the altered NRG1–ErbB4 signalling may induce functional changes of the 
NMDA receptor via the Src pathway. In the case of elevated NRG1–ErbB4 signalling, 
as shown in many post-mortem brain studies (reviewed above), it may induce NMDA 
receptor hypofunction via the Src pathway, which may act directly on pyramidal 
neurons or indirectly through GABAergic interneurons (Fig. 1) (Hahn 2011; Pitcher et 
al. 2011). However, it should also be noted that some studies reported a decreased 
expression of NRG1 (Bertram et al. 2007; Hashimoto et al. 2004). As discussed above, 
NRG1–ErbB4 signalling can activate Fyn and Pyk2 kinases leading to increased 
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NMDA NR2B phosphorylation (Bjarnadottir et al. 2007), whereas hypofunction of 
NRG1–ErbB4 signalling will cause decreased activation of Fyn and Pyk2 kinases and 
NMDA phosphorylation, resulting abnormal modulation of glutamatergic 
neurotransmission. This may also partly contribute to the pathophysiology of 
schizophrenia (Bjarnadottir et al. 2007). Therefore, both increased and decreased 
NRG1–ErbB4 signalling may lead to NMDA hypofunction. As presented in Fig. 1, 
NMDA hypofunction may lead to deficits in GABAergic transmission by down-
regulating GAD67 (67-kDa isoform of glutamic acid decarboxylase) and decreasing 
GABA production, which in turn cause further decreased excitatory activity of 
pyramidal cells in the frontal cortex and ventral hippocampus. In fact, GAD67 was 
decreased in ErbB4 knockout mice (Neddens and Buonanno 2010). Both NMDA 
hypofunction and decreased excitatory projections from the frontal 
cortex/hippocampus may lead to deficits of dopaminergic transmission in the 
midbrain, which may affect pyramidal activity. The interactions between NRG1–
ErbB4 signalling and neurotransmission pathways may not only contribute to the 
pathophysiology of schizophrenia, but also provide potential targets for schizophrenia 
medication (see below). 
 
4. THE  EFFECTS  OF  ANTIPSYCHOTIC  TREATMENT  ON  NRG1­
ERBB4 SIGNALLING  
 
Individuals with schizophrenia that have different NRG1 genotypes respond 
differently to typical antipsychotic drugs (Kampman et al. 2004). However, to date, 
there has been no systematic investigation on the effects of antipsychotic treatment on 
NRG1–ErbB4 signalling, even though several studies have reported antipsychotic 
drugs affect protein levels and mRNA expression of NRG1 and the ErbB4 receptor in 
both animals and humans. An in vivo study using haloperidol, clozapine and 
risperidone for 4 weeks in rats reported that haloperidol increased the protein levels of 
total NRG1 and ErbB4 receptors, while clozapine reduced the protein expression of 
NRG1 in the PFC; however all three antipsychotic drugs increased NRG1 and ErbB4 
protein expression in the hippocampus (Wang et al. 2008). On the other hand, 12-
week treatment with haloperidol significantly reduces NRG1-induced ErbB4 
activation in the PFC of mice (Hahn et al. 2006). Additionally, protein expression of 
NRG1 in the human fetal brain aggregates (in vitro) was increased following a 3-
week exposure to clozapine, but not after haloperidol treatment (Chana et al. 2009). 
Furthermore, 2-week treatment with risperidone and quetiapine significantly increases 
NRG1 mRNA expression in PBLs in first-onset schizophrenia patients (Zhang et al. 
2008, 2011). However, NRG1 type I protein in monkey serum did not change after 8-
week treatment with haloperidol (Shibuya et al. 2010). Together, these studies show a 
trend where short-term treatment with antipsychotics (up to 4 weeks) increases the 
expression (mRNA or protein) of NRG1 and ErbB4 receptors, while prolonged 
antipsychotic treatment may decrease their expression. However, different 
experimental conditions (i.e., different antipsychotics and various types of tissue 
tested) may explain the contrasting findings reported in these studies. Furthermore, 
although all current antipsychotic drugs target dopamine D2 receptors, they do have 
different pharmacological profiles. For example, although haloperidol, risperidone, 
clozapine and quetiapine are D2 antagonists, haloperidol (Ki=2.6) and risperidone 
(Ki=3.77) have much higher binding affinities to D2 receptors than clozapine 
(Ki=210) and quetiapine (Ki=770) (Correll 2010). On the other hand, clozapine 
displays high affinity to 5-HT2A (Ki=2.59) and 5-HT2C (Ki=4.8) receptors, while 
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risperidone has a high affinity to 5-HT2A (Ki=0.15) and moderate affinity to 5-HT2C 
(Ki=32), and quetiapine has a moderate affinity to 5-HT2A (Ki=31), but no affinity to 
5-HT2C (Ki=3500) (Correll 2010). It has been suggested that antagonism of serotonin 
5-HT2A, 2C receptors (which interact with dopamine D2 receptor antagonism), is a 
mechanism to achieve clinical efficacy of atypical antipsychotic drugs (Mathews and 
David 2007; Meltzer and Massey 2011). Therefore, the differential effects of various 
antipsychotic drugs on NRG1–ErbB4 expression may partly be explained by their 
distinct pharmacological profiles. 
 
Antipsychotic drugs can not only affect NRG1–ErbB4 signalling, but are also able to 
reverse abnormal behaviours in animal models of schizophrenia with impaired 
NRG1– ErbB4 signalling. For example, clozapine is effective at reversing the 
hyperactivity in TMN domain mutant mice (Stefansson et al. 2002), Ig-like domain 
mutant mice (Dejaegere et al. 2008), BACE1-knockout mice (Savonenko et al. 2008) 
and ErbB4-deficient animals (Barros et al. 2009). Clozapine is also effective at 
normalising abnormal lateral inhibition in NRG1 Ig-like domain mutant mice (Rimer 
et al. 2005). Furthermore, PPI deficits can be improved by both haloperidol and 
clozapine in Aph1B/C-γ-secretase-disturbed mice (Dejaegere et al. 2008), and by 
clozapine in BACE1-knockout mice (Savonenko et al. 2008) and ErbB4-deficient 
mice (Barros et al. 2009). A recent study has reported that PPI deficits caused by 
neonatal treatment of NRG1 could be ameliorated by chronic treatment of risperidone 
(Kato et al. 2011). Although the mechanism underlying antipsychotic corrections of 
these behavioural deficits is not clear, it is likely to be via modulation of the 
interactions between NRG1–ErbB4 pathways and neurotransmission pathways. For 
example, several studies have shown that phosphorylation of the NR2B subunit was 
inhibited in mice with TMN domain NRG1+/− mutation and ErbB4+/− mutation, and 
this defect could be reversed by clozapine treatment (Bjarnadottir et al. 2007; 
Moghaddam 2003). 
 
5. NRG1  AS  A  POTENTIAL  THERAPEUTIC  TREATMENT  FOR 
PSYCHOTIC SYMPTOMS  
 
As described above, several mutations in NRG1–ErbB4 signalling genes are 
associated with different clinically relevant phenotypes, such as prepulse inhibition, 
startle habituation, working memory, frontal lobe activation, and alterations in other 
cognitive functions (Greenwood et al. 2012; Hall et al. 2006; Konrad et al. 2009; 
Munafo et al. 2006; Yokley et al. 2012). Therefore, there is potential for the use of 
NRG1 as a novel treatment option for patients with psychotic symptoms. Two proof-
of-concept studies for NRG1 treatment have been published by two independent 
laboratories, confirming that peripherally administered NRG1 can pass the blood–
brain barrier, most likely via a receptor-mediated transport mechanism (Kastin et al. 
2004; Rösler et al. 2011). The rapid uptake of peripheral NRG1 enables time-sensitive 
treatment schedules, making NRG1 available both for acute and long-term treatment 
schemes, as shown by neuroprotective effects following intravascular administration 
in acute stroke models (Xu et al. 2004, 2006). 
 
Animal studies have highlighted the time-sensitive effect of NRG1 administration on 
neurodevelopment and behaviours. The long-lasting effects of postnatal NRG1 
treatment have been assessed by Kato et al. (2011), who peripherally administered 
NRG1 to newborn mice from postnatal days (PND) 2–10, which triggered an 
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immediate increase in dopamine content and TH phosphorylation in the frontal cortex, 
and a similar increase in the striatum at PND 11, with no changes in glutamatergic or 
GABAergic neurotransmitter system proteins (Kato et al. 2011). The increase in 
NRG1 activity during the corticolimbic fibre growing period resulted in long-lasting 
effects beyond adolescence. The dopaminergic system remained altered with 
increased dopamine metabolite levels in the adult frontal cortex and increased 
dopamine release in this area (Kato et al. 2011). NRG1-treated mice displayed 
reduced social interaction in adulthood as well as a lack of latent inhibition and 
impaired PPI (Kato et al. 2011). 
 
In contrast to the harmful consequences of NRG1 exposure during the developmental 
period, three recent studies observed a potentially beneficial effect of NRG1 
administration during adulthood. Adult mice receiving subcutaneous NRG1 for 3 days 
showed increased cell proliferation and neurogenesis in the hippocampal dentate 
gyrus as well as improved performance in the forced swim test (Mahar et al. 2011). 
The antidepressant-like effect of NRG1 treatment appears to be the consequence of an 
increase in neurogenesis, with the behavioural differences only visible 4 weeks after 
treatment cessation and not acutely after administration (Mahar et al. 2011). Recent 
work on a mouse model for Parkinson’s disease provides further evidence for 
potentially beneficial neurotrophic effects of peripheral NRG1 administration 
(Carlsson et al. 2011). Modelling the reduction of mesencephalic dopaminergic 
neurons in patients with Parkinson’s disease, Carlsson and colleagues injected NRG1 
intraperitoneally (i.p.) to adult mice for 8 days immediately after a neurotoxin 6-
OHDA injection into the striatum (Carlsson et al. 2011). Instant treatment onset (6 h 
after 6-OHDA) of NRG1 attenuated the decrease of dopamine producing neurons in 
the SN as well as lesion-related behavioural changes (Carlsson et al. 2011). Although 
no clinical trial has been conducted to test the potential of NRG1 as a treatment option 
for psychosis in humans, two recent successful phase II chronic trials using NRG1 to 
treat heart failure strongly support the safety and tolerability of NRG1 treatment in a 
clinical setting (Gao et al. 2010; Jabbour et al. 2011). 
 
6. POTENTIAL  TARGETS  IN  NRG1­ERBB4  SIGNALLING  AND 
RELATED  PATHWAYS  FOR  NEXT  GENERATION  OF 
ANTIPSYCHOTIC DRUGS  
 
As discussed, significant progress has been achieved over the past several years 
towards revealing the mechanistic roles of NRG1–ErbB4 signalling in the 
pathophysiology of schizophrenia. These findings have identified potential targets that 
provide insights for the development of a new generation of antipsychotic drugs. 
Firstly, the recent finding that peripheral NRG1 treatment displayed antidepressant-
like effects in adult animals (Mahar et al. 2011) suggests a potential to develop 
molecules/ligands that bind to and modulate ErbB receptors. However, this approach 
should be taken with caution due to the inverted U-shaped relationship between 
ErbB4 activity and the expression of schizophrenia endophenotypes (Hahn 2011; Role 
and Talmage 2007; Wen et al. 2010), as well as different effects of NRG1 treatment 
in developing and adult animals (Kato et al. 2011; Mahar et al. 2011). Secondly, it is 
possible to examine more specific targets within the downstream pathways of NRG1–
ErbB4 signalling. The recent finding, that NRG1–ErbB4 signalling inhibits Src-
mediated enhancement of synaptic NMDA function, provides novel targets in the 
frontal cortex and hippocampus for new antipsychotic drugs (Pitcher et al. 2011), 
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since the majority of studies have showed that schizophrenia patients have increased 
NRG1– ErbB4 signalling (Hahn 2011). Therefore, a drug aimed at specifically 
restoring Src activity in schizophrenia could potentially be a new approach for 
schizophrenia therapy (Fig. 1) (Hahn 2011; Pitcher et al. 2011). On the other hand, it 
should be noted that some studies reported decreased expression of NRG1 (as 
reviewed above); if this is the case, this may lead to different therapeutic approaches 
in schizophrenia patients with decreased NRG1–ErbB4 signalling by activating Fyn 
and Pyk2 kinases (Bjarnadottir et al. 2007). Thirdly, the finding that ErbB4 receptors 
are located on PV-positive GABA interneurons in the frontal cortex and hippocampus, 
a trait conserved between species from rodents to humans, provides another specific 
approach for the development of antipsychotics by enhancing the function of PV-
positive GABA interneurons. For example, PV-positive interneurons present a 5-fold 
higher NR2A/NR2B ratio than pyramidal neurons, and these NR2A-containing 
NMDA receptors regulate the expression of GAD67 in PV-positive GABA 
interneurons (Kinney et al. 2006). The density of a subset of GABA interneurons with 
co-expression of GAD67 and NR2A is decreased in the prefrontal and anterior 
cingulated cortex of schizophrenic patients (Woo et al. 2004, 2008). Therefore, a drug 
that selectively activates NR2A-containing NMDA receptors in PV-positive 
interneurons could have therapeutic value to reverse the NMDA hypofunction 
observed in patients with schizophrenia (Lewis and Gonzalez-Burgos 2006; Rico and 
Marin 2011). In addition, a drug to modulate interactions between NRG1–ErbB4 
signalling and the dopamine pathway may also be a valuable approach to 
schizophrenia therapy. 
 
Furthermore, the interactive points between NRG1 and other schizophrenia 
susceptibility factors/pathways should not be excluded as possible future drug targets, 
as research over the last decade has clearly shown that no single risk factor or related 
pathway for schizophrenia can cause the disease, instead cumulative or synergistic 
pathological effects seem likely (Balu and Coyle 2011; Karam et al. 2010). One 
example is the interaction between ErbB4 and DISC1, due to their co-localisation in 
the PSD of glutamate synapses and possible functional convergence (Hashimoto et al. 
2007; Jaaro-Peled et al. 2009). Targeting both the NRG1–ErbB4 and DISC1–GSK3–
Akt pathways may provide specific targets for new antipsychotic drugs (Jaaro-Peled 
et al. 2009; Ross and Margolis 2009). In addition, other schizophrenia susceptibility 
factors, such as dysbindin-1, neuronal nitric oxide synthase (nNOS), carboxyl-
terminal PDZ ligand of neuronal nitric oxide synthase (CAPON), and growth factor 
receptor bound protein (Grb2), are also located in the PSD where signals from 
neurotransmitters converge, making PSD itself a promising drug discovery target 
(Hashimoto et al. 2007; Jaaro-Peled et al. 2009). In conclusion, identification of these 
targets in NRG1–ErbB4 signalling and interacting pathways will provide unique 
opportunities for the development of new generation antipsychotics with specific 
efficacy and fewer side effects. 
 
ACKNOWLEDGEMENTS 
This study was supported by a University of Wollongong URC grant and an NHMRC 
project grant (APP1008473) to C. Deng, and the Schizophrenia Research Institute, 
Australia, utilising infrastructure funding from NSW Health. We would like to thank 
Dr Katrina Green for her critical reading of this manuscript. 
 





Abe Y, Namba H, Zheng Y, Nawa H (2009): In situ hybridization reveals 
developmental regulation of ErbB1-4 mRNA expression in mouse midbrain: 
implication of ErbB receptors for dopaminergic neurons. Neuroscience 161:95-
110. 
Anton ES, Marchionni MA, Lee KF, Rakic P (1997): Role of GGF/neuregulin 
signaling in interactions between migrating neurons and radial glia in the 
developing cerebral cortex. Development 124:3501-3510. 
Austin J (2005): Schizophrenia: an update and review. Journal of Genetic Counseling 
14:329-340. 
Balu DT, Coyle JT (2011): Neuroplasticity signaling pathways linked to the 
pathophysiology of schizophrenia. Neurosci Biobehav Rev 35:848-870. 
Bao J, Wolpowitz D, Role LW, Talmage DA (2003): Back signaling by the Nrg-1 
intracellular domain. J Cell Biol 161:1133-1141. 
Barakat A, Dean B, Scarr E, Evin G (2010): Decreased Neuregulin 1 C-terminal 
fragment in Brodmann's area 6 of patients with schizophrenia. Schizophrenia 
Research 124:200-207. 
Bare DJ, Becker-Catania SG, DeVries GH (2011): Differential localization of 
neuregulin-1 type III in the central and peripheral nervous system. Brain 
Research 1369:10-20. 
Barros CS, Calabrese B, Chamero P, Roberts AJ, Korzus E, Lloyd K, et al (2009): 
Impaired maturation of dendritic spines without disorganization of cortical cell 
layers in mice lacking NRG1/ErbB signaling in the central nervous system. 
Proceedings of the National Academy of Sciences of the United States of 
America 106:4507-4512. 
Benes FM (2009): Neural Circuitry Models of Schizophrenia: Is it Dopamine, GABA, 
Glutamate, or Something Else? Biological Psychiatry 65:1003-1005. 
Bermingham-McDonogh O, McCabe KL, Reh TA (1996): Effects of 
GGF/neuregulins on neuronal survival and neurite outgrowth correlate with 
erbB2/neu expression in developing rat retina. Development 122:1427-1438. 
Bernstein H-G, Lendeckel U, Bertram I, Bukowska A, Kanakis D, Dobrowolny H, et 
al (2006): Localization of neuregulin-1β (heregulin-β) and one of its receptors, 
ErbB-4 tyrosine kinase, in developing and adult human brain. Brain Research 
Bulletin 69:546-559. 
Bertram I, Bernstein HG, Lendeckel U, Bukowska A, Dobrowolny H, Keilhoff G, et 
al (2007): Immunohistochemical evidence for impaired neuregulin-1 signaling 
in the prefrontal cortex in schizophrenia and in unipolar depression. Ann N Y 
Acad Sci 1096:147-156. 
Bjarnadottir M, Misner DL, Haverfield-Gross S, Bruun S, Helgason VG, Stefansson 
H, et al (2007): Neuregulin1 (NRG1) signaling through Fyn modulates NMDA 
receptor phosphorylation: differential synaptic function in NRG1+/- knock-outs 
compared with wild-type mice. J Neurosci 27:4519-4529. 
Bublil EM, Yarden Y (2007): The EGF receptor family: spearheading a merger of 
signaling and therapeutics. Current Opinion in Cell Biology 19:124-134. 
Buonanno A (2010): The neuregulin signaling pathway and schizophrenia: from 
genes to synapses and neural circuits. Brain Res Bull 83:122-131. 
Calaora V, Rogister B, Bismuth K, Murray K, Brandt H, Leprince P, et al (2001): 
Neuregulin signaling regulates neural precursor growth and the generation of 
oligodendrocytes in vitro. J Neurosci 21:4740-4751. 
16 
 
Canoll PD, Musacchio JM, Hardy R, Reynolds R, Marchionni MA, Salzer JL (1996): 
GGF/neuregulin is a neuronal signal that promotes the proliferation and survival 
and inhibits the differentiation of oligodendrocyte progenitors. Neuron 17:229-
243. 
Carlsson T, Schindler FR, Hollerhage M, Depboylu C, Arias-Carrion O, 
Schnurrbusch S, et al (2011): Systemic administration of neuregulin-1beta1 
protects dopaminergic neurons in a mouse model of Parkinson's disease. 
Journal of Neurochemistry 117:1066-1074. 
Chana G, Lucero G, Salaria S, Lozach J, Du P, Woelk C, Everall I (2009): 
Upregulation of NRG-1 and VAMP-1 in human brain aggregates exposed to 
clozapine. Schizophr Res 113:273-276. 
Chen B-S, Braud S, Badger JD, Isaac JTR, Roche KW (2006): Regulation of 
NR1/NR2C N-Methyl-D-aspartate (NMDA) Receptors by Phosphorylation. 
Journal of Biological Chemistry 281:16583-16590. 
Chen Y-J, Zhang M, Yin D-M, Wen L, Ting A, Wang P, et al (2010a): ErbB4 in 
parvalbumin-positive interneurons is critical for neuregulin 1 regulation of long-
term potentiation. Proceedings of the National Academy of Sciences of the 
United States of America 107:21818-21823. 
Chen Y-JJ, Johnson MA, Lieberman MD, Goodchild RE, Schobel S, Lewandowski 
N, et al (2008): Type III Neuregulin-1 Is Required for Normal Sensorimotor 
Gating, Memory-Related Behaviors, and Corticostriatal Circuit Components. 
The Journal of Neuroscience 28:6872-6883. 
Chen Y, Hancock ML, Role LW, Talmage DA (2010b): Intramembranous valine 
linked to schizophrenia is required for neuregulin 1 regulation of the 
morphological development of cortical neurons. J Neurosci 30:9199-9208. 
Chesworth R, Downey L, Logge W, Killcross S, Karl T (2012): Cognition in female 
transmembrane domain neuregulin 1 mutant mice. Behav Brain Res 226:218-
223. 
Chong VZ, Thompson M, Beltaifa S, Webster MJ, Law AJ, Weickert CS (2008): 
Elevated neuregulin-1 and ErbB4 protein in the prefrontal cortex of 
schizophrenic patients. Schizophrenia Research 100:270-280. 
Cooper MA, Koleske AJ (2011): ErbB4 localization to interneurons: clearer insights 
into schizophrenia pathology. Biological Psychiatry 70:602-603. 
Correll CU (2010): From receptor pharmacology to improved outcomes: 
individualising the selection, dosing, and switching of antipsychotics. European 
Psychiatry 25, Supplement 2:S12-S21. 
Cousins SL, Kenny AV, Stephenson FA (2009): Delineation of additional PSD-95 
binding domains within NMDA receptor NR2 subunits reveals differences 
between NR2A/PSD-95 and NR2B/PSD-95 association. Neuroscience 158:89-
95. 
Deakin IH, Law AJ, Oliver PL, Schwab MH, Nave KA, Harrison PJ, Bannerman DM 
(2009): Behavioural characterization of neuregulin 1 type I overexpressing 
transgenic mice. Neuroreport 20:1523-1528. 
Dejaegere T, Serneels L, Schäfer MK, Van Biervliet J, Horré K, Depboylu C, et al 
(2008): Deficiency of Aph1B/C-γ-secretase disturbs Nrg1 cleavage and 
sensorimotor gating that can be reversed with antipsychotic treatment. Proc Natl 
Acad Sci U S A 105:9775-9780. 
Deng C, Huang X-F (2006): Increased density of GABAA receptors in the superior 
temporal gyrus in schizophrenia. Exp Brain Res 168:587-590. 
17 
 
Deng C, Weston-Green K, Huang X-F (2010): The role of histaminergic H1 and H3 
receptors in food intake: A mechanism for atypical antipsychotic-induced 
weight gain? Progress in Neuro-Psychopharmacology and Biological 
Psychiatry 34:1-4. 
Desbonnet L, Waddington JL, O'Tuathaigh CMP (2009): Mutant models for genes 
associated with schizophrenia. Biochem Soc Trans 37:308-312. 
Duffy L, Cappas E, Lai D, Boucher AA, Karl T (2010): Cognition in transmembrane 
domain neuregulin 1 mutant mice. Neuroscience 170:800-807. 
Duffy L, Cappas E, Scimone A, Schofield PR, Karl T (2008): Behavioral profile of a 
heterozygous mutant mouse model for EGF-like domain neuregulin 1. 
Behavioral Neuroscience 122:748-759. 
Falls DL (2003): Neuregulins : functions, forms, and signaling strategies. 
Experimental Cell Research 284:14-30. 
Fatemi SH, Folsom TD (2009): The Neurodevelopmental Hypothesis of 
Schizophrenia, Revisited. Schizophrenia Bulletin. 
Fazzari P, Paternain AV, Valiente M, Pla R, Lujan R, Lloyd K, et al (2010): Control 
of cortical GABA circuitry development by Nrg1 and ErbB4 signalling. Nature 
464:1376-1380. 
Gao R, Zhang J, Cheng L, Wu X, Dong W, Yang X, et al (2010): A Phase II, 
Randomized, Double-Blind, Multicenter, Based on Standard Therapy, Placebo-
Controlled Study of the Efficacy and Safety of Recombinant Human 
Neuregulin-1 in Patients With Chronic Heart Failure. J Am Coll Cardiol 
55:1907-1914. 
Garcia-Barcelo M-M, Miao X, Tang CS, So H-C, Tang W, Leon TYY, et al (2011): 
No NRG1 V266L in Chinese patients with schizophrenia. Psychiatr Genet 
21:47-49. 
Garcia RAG, Vasudevan K, Buonanno A (2000): The neuregulin receptor ErbB-4 
interacts with PDZ-containing proteins at neuronal synapses. Proceedings of the 
National Academy of Sciences 97:3596-3601. 
Geddes AE, Huang X-F, Newell KA (2011): Reciprocal signalling between NR2 
subunits of the NMDA receptor and neuregulin1 and their role in schizophrenia. 
Prog Neuropsychopharmacol Biol Psychiatry 35:896-904. 
Gerecke KM, Wyss JM, Carroll SL (2004): Neuregulin-1beta induces neurite 
extension and arborization in cultured hippocampal neurons. Mol Cell Neurosci 
27:379-393. 
Gerlai R, Pisacane P, Erickson S (2000): Heregulin, but not ErbB2 or ErbB3, 
heterozygous mutant mice exhibit hyperactivity in multiple behavioral tasks. 
Behav Brain Res 109:219-227. 
Greenwood TA, Light GA, Swerdlow NR, Radant AD, Braff DL (2012): Association 
analysis of 94 candidate genes and schizophrenia-related endophenotypes. PLoS 
ONE [Electronic Resource] 7:e29630. 
Gu Z, Jiang Q, Fu A, Ip N, Yan Z (2005): Regulation of NMDA receptors by 
neuregulin signaling in prefrontal cortex. The Journal of Neuroscience 25:4974-
4984. 
Hahn C-G (2011): A Src link in schizophrenia. Nat Med 17:425-427. 
Hahn CG, Wang HY, Cho DS, Talbot K, Gur RE, Berrettini WH, et al (2006): 
Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor 
hypofunction in schizophrenia. Nat Med 12:824-828. 
18 
 
Hall J, Whalley HC, Job DE, Baig BJ, McIntosh AM, Evans KL, et al (2006): A 
neuregulin 1 variant associated with abnormal cortical function and psychotic 
symptoms. Nat Neurosci 9:1477-1478. 
Hashimoto R, Straub R, Weickert C, Hyde T, Kleinman J, Weinberger D (2004): 
Expression analysis of neuregulin-1 in the dorsolateral prefrontal cortex in 
schizophrenia. Molecular Psychiatry 9:299-307. 
Hashimoto R, Tankou S, Takeda M, Sawa A (2007): Postsynaptic density: a key 
convergent site for schizophrenia susceptibility factors and possible target for 
drug development. Drugs of Today (Barc) 43:645-654. 
 Hong LE, Wonodi I, Stine OC, Mitchell BD, Thaker GK (2008): Evidence of 
missense mutations on the neuregulin 1 gene affecting function of prepulse 
inhibition. Biological Psychiatry 63:17-23. 
Hu X, Hicks CW, He W, Wong P, Macklin WB, Trapp BD, Yan R (2006): Bace1 
modulates myelination in the central and peripheral nervous system. Nat 
Neurosci 9:1520-1525. 
Huang YZ, Won S, Ali DW, Wang Q, Tanowitz M, Du QS, et al (2000): Regulation 
of neuregulin signaling by PSD-95 interacting with ErbB4 at CNS synapses. 
Neuron 26:443-455. 
Ikeda M, Takahashi N, Saito S, Aleksic B, Watanabe Y, Nunokawa A, et al (2008): 
Failure to replicate the association between NRG1 and schizophrenia using 
Japanese large sample. Schizophrenia Research 101:1-8. 
Ingason A, Soeby K, Timm S, Wang AG, Jakobsen KD, Fink-Jensen A, et al (2006): 
No significant association of the 5' end of neuregulin 1 and schizophrenia in a 
large Danish sample. Schizophrenia Research 83:1-5. 
Jaaro-Peled H, Hayashi-Takagi A, Seshadri S, Kamiya A, Brandon NJ, Sawa A 
(2009): Neurodevelopmental mechanisms of schizophrenia: understanding 
disturbed postnatal brain maturation through neuregulin-1-ErbB4 and DISC1. 
Trends in Neurosciences 32:485-495. 
Jabbour A, Hayward CS, Keogh AM, Kotlyar E, McCrohon JA, England JF, et al 
(2011): Parenteral administration of recombinant human neuregulin-1 to 
patients with stable chronic heart failure produces favourable acute and chronic 
haemodynamic responses. Eur J Heart Fail 13:83-92. 
Jones JT, Akita RW, Sliwkowski MX (1999): Binding specificities and affinities of 
egf domains for ErbB receptors. FEBS letters 447:227-231. 
Jonsson EG, Saetre P, Vares M, Andreou D, Larsson K, Timm S, et al (2009): 
DTNBP1, NRG1, DAOA, DAO and GRM3 polymorphisms and schizophrenia: 
an association study. Neuropsychobiology 59:142-150. 
Junttila TT, Sundvall M, Maatta JA, Elenius K (2000): Erbb4 and its isoforms: 
selective regulation of growth factor responses by naturally occurring receptor 
variants. Trends in cardiovascular medicine 10:304-310. 
Kainulainen V, Sundvall M, Maatta JA, Santiestevan E, Klagsbrun M, Elenius K 
(2000): A natural ErbB4 isoform that does not activate phosphoinositide 3-
kinase mediates proliferation but not survival or chemotaxis. The Journal of 
biological chemistry 275:8641-8649. 
Kampman O, Anttila S, Illi A, Saarela M, Rontu R, Mattila KM, et al (2004): 
Neuregulin genotype and medication response in Finnish patients with 
schizophrenia. Neuroreport 15:2517-2520. 
Kanazawa T, Glatt SJ, Tsutsumi A, Kikuyama H, Koh J, Yoneda H, Tsuang MT 
(2007): Schizophrenia is not associated with the functional candidate gene 
19 
 
ERBB3: results from a case-control study. Am J Med Genet B Neuropsychiatr 
Genet 144B:113-116. 
Kang C, Yang X, Xu X, Liu H, Su P, Yang J (2012): Association study of neuregulin 
1 gene polymorphisms with auditory P300 in schizophrenia. Am J Med Genet B 
Neuropsychiatr Genet 159B:422-428. 
Kantrowitz JT, Javitt DC (2010): N-methyl-d-aspartate (NMDA) receptor dysfunction 
or dysregulation: The final common pathway on the road to schizophrenia? 
Brain Research Bulletin 83:108-121. 
Karam CS, Ballon JS, Bivens NM, Freyberg Z, Girgis RR, Lizardi-Ortiz JE, et al 
(2010): Signaling pathways in schizophrenia: emerging targets and therapeutic 
strategies. Trends in Pharmacological Sciences 31:381-390. 
Karl T, Duffy L, Scimone A, Harvey RP, Schofield PR (2007): Altered motor 
activity, exploration and anxiety in heterozygous neuregulin 1 mutant mice: 
implications for understanding schizophrenia. Genes Brain Behav 6:677-687. 
Kastin AJ, Akerstrom V, Pan W (2004): Neuregulin-1-β1 enters brain and spinal cord 
by receptor-mediated transport. Journal of Neurochemistry 88:965-970. 
Kato T, Abe Y, Sotoyama H, Kakita A, Kominami R, Hirokawa S, et al (2011): 
Transient exposure of neonatal mice to neuregulin-1 results in 
hyperdopaminergic states in adulthood: implication in neurodevelopmental 
hypothesis for schizophrenia. Molecular Psychiatry 16:307-320. 
Kato T, Kasai A, Mizuno M, Fengyi L, Shintani N, Maeda S, et al (2010): Phenotypic 
characterization of transgenic mice overexpressing neuregulin-1. PLoS ONE 
[Electronic Resource] 5:e14185. 
Kinney JW, Davis CN, Tabarean I, Conti B, Bartfai T, Behrens MM (2006): A 
Specific Role for NR2A-Containing NMDA Receptors in the Maintenance of 
Parvalbumin and GAD67 Immunoreactivity in Cultured Interneurons. The 
Journal of Neuroscience 26:1604-1615. 
Kiss I, Kelemen O, KÃ©ri S (2012): Decreased peripheral expression of neuregulin 1 
in high-risk individuals who later converted to psychosis. Schizophrenia 
Research 135:198-199. 
Konrad A, Vucurevic G, Musso F, Stoeter P, Dahmen N, Winterer G (2009): ErbB4 
genotype predicts left frontotemporal structural connectivity in human brain. 
Neuropsychopharmacology 34:641-650. 
Krivosheya D, Tapia L, Levinson JN, Huang K, Kang Y, Hines R, et al (2008): 
ErbB4-neuregulin signaling modulates synapse development and dendritic 
arborization through distinct mechanisms. Journal of Biological Chemistry 
283:32944-32956. 
Kwon OB, Longart M, Vullhorst D, Hoffman DA, Buonanno A (2005): Neuregulin-1 
reverses long-term potentiation at CA1 hippocampal synapses. J Neurosci 
25:9378-9383. 
Kwon OB, Paredes D, Gonzalez CM, Neddens J, Hernandez L, Vullhorst D, 
Buonanno A (2008): Neuregulin-1 regulates LTP at CA1 hippocampal synapses 
through activation of dopamine D4 receptors. Proc Natl Acad Sci U S A 
105:15587-15592. 
Lang UE, Puls I, Muller DJ, Strutz-Seebohm N, Gallinat J (2007): Molecular 
mechanisms of schizophrenia. Cell Physiol Biochem 20:687-702. 
Law AJ, Kleinman JE, Weinberger DR, Weickert CS (2007): Disease-associated 
intronic variants in the ErbB4 gene are related to altered ErbB4 splice-variant 




Law AJ, Lipska BK, Weickert CS, Hyde TM, Straub RE, Hashimoto R, et al (2006): 
Neuregulin 1 transcripts are differentially expressed in schizophrenia and 
regulated by 5' SNPs associated with the disease. The National Academy of 
Sciences of the USA 103:6747-6752  
Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009): Second-generation 
versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. 
Lancet 373:31-41. 
Lewis DA, Gonzalez-Burgos G (2006): Pathophysiologically based treatment 
interventions in schizophrenia. Nat Med 12:1016-1022. 
Lewis DA, Moghaddam B (2006): Cognitive Dysfunction in Schizophrenia: 
Convergence of {gamma}-Aminobutyric Acid and Glutamate Alterations. Arch 
Neurol 63:1372-1376. 
Li D, Collier DA, He L (2006): Meta-analysis shows strong positive association of the 
neuregulin 1 (NRG1) gene with schizophrenia. Hum Mol Genet 15:1995-2002. 
Li D, Feng G, He L (2009a): Case-control study of association between the functional 
candidate gene ERBB3 and schizophrenia in Caucasian population. The world 
journal of biological psychiatry : the official journal of the World Federation of 
Societies of Biological Psychiatry 10:595-598. 
Li D, He G, Xu Y, Duan Y, Gu N, Li X, et al (2009b): Schizophrenia is not associated 
with the ERBB3 gene in a Han Chinese population sample: Results from case-
control and family-based studies. Genetics and molecular biology 32:729-730. 
Lipska BK, Lerman DN, Khaing ZZ, Weinberger DR (2003): The neonatal ventral 
hippocampal lesion model of schizophrenia: effects on dopamine and GABA 
mRNA markers in the rat midbrain. Eur J Neurosci 18:3097-3104. 
Liu C-M, Hwu H-G, Fann CSJ, Lin C-Y, Liu Y-L, Ou-Yang W-C, Lee SFC (2005): 
Linkage evidence of schizophrenia to loci near neuregulin 1 gene on 
chromosome 8p21 in Taiwanese families. American Journal of Medical 
Genetics Part B: Neuropsychiatric Genetics 134B:79-83. 
Liu X, Bates R, Yin D-M, Shen C, Wang F, Su N, et al (2011): Specific regulation of 
NRG1 isoform expression by neuronal activity. J Neurosci 31:8491-8501. 
Long LE, Chesworth R, Arnold JC, Karl T (2010a): A follow-up study: acute 
behavioural effects of Delta(9)-THC in female heterozygous neuregulin 1 
transmembrane domain mutant mice. Psychopharmacology (Berl) 211:277-289. 
Long LE, Chesworth R, Huang X-F, McGregor IS, Arnold JC, Karl T (2010b): A 
behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and 
cannabidiol in C57BL/6JArc mice. International Journal of 
Neuropsychopharmacology 13:861-876. 
Lopez-Bendito G, Cautinat A, Sanchez JA, Bielle F, Flames N, Garratt AN, et al 
(2006): Tangential neuronal migration controls axon guidance: a role for 
neuregulin-1 in thalamocortical axon navigation. Cell 125:127-142. 
Lu C-L, Wang Y-C, Chen J-Y, Lai IC, Liou Y-J (2010): Support for the involvement 
of the ERBB4 gene in schizophrenia: a genetic association analysis. 
Neuroscience Letters 481:120-125. 
Mahar I, Tan S, Davoli MA, Dominguez-Lopez S, Qiang C, Rachalski A, et al (2011): 
Subchronic peripheral neuregulin-1 increases ventral hippocampal neurogenesis 
and induces antidepressant-like effects. PLoS ONE [Electronic Resource] 
6:e26610. 
Mathews M, David JM (2007): Atypical antipsychotics: New drugs, new challenges. 
Cleveland Clinic Journal of Medicine 74:579-606. 
21 
 
Mei L, Xiong W-C (2008): Neuregulin 1 in neural development, synaptic plasticity 
and schizophrenia. Nature Reviews 9:437-452. 
Meltzer HY, Massey BW (2011): The role of serotonin receptors in the action of 
atypical antipsychotic drugs. Current Opinion in Pharmacology 11:59-67. 
Michailov GV, Sereda MW, Brinkmann BG, Fischer TM, Haug B, Birchmeier C, et 
al (2004): Axonal neuregulin-1 regulates myelin sheath thickness. Science (New 
York, NY) 304:700-703. 
Moghaddam B (2003): Bringing order to the glutamate chaos in schizophrenia. 
Neuron 40:881-884. 
Montero JC, Rodriguez-Barrueco R, Yuste L, Juanes PP, Borges J, Esparis-Ogando 
A, Pandiella A (2007): The Extracellular Linker of pro-Neuregulin-{alpha}2c Is 
Required for Efficient Sorting and Juxtacrine Function. Mol Biol Cell 18:380-
393. 
Munafo MR, Thiselton DL, Clark TG, Flint J (2006): Association of the NRG1 gene 
and schizophrenia: a meta-analysis. Molecular Psychiatry 11:539-546. 
Murray CJ, Lopez AD (1996): The Global Burden of Disease: a comprehensive 
assessment of mortality and disability from diseases, injuries and risk factors in 
1990 and projected to 2020. Cambridge, MA: Harvard School of Public Health. 
Nason MW, Jr., Adhikari A, Bozinoski M, Gordon JA, Role LW (2011): Disrupted 
activity in the hippocampal-accumbens circuit of type III neuregulin 1 mutant 
mice. Neuropsychopharmacology 36:488-496. 
Nave KA, Salzer JL (2006): Axonal regulation of myelination by neuregulin 1. Curr 
Opin Neurobiol 16:492-500. 
Neddens J, Buonanno A (2010): Selective populations of hippocampal interneurons 
express ErbB4 and their number and distribution is altered in ErbB4 knockout 
mice. Hippocampus 20:724-744. 
Neddens J, Fish KN, Tricoire L, Vullhorst D, Shamir A, Chung W, et al (2011a): 
Conserved Interneuron-Specific ErbB4 Expression in Frontal Cortex of 
Rodents, Monkeys, and Humans: Implications for Schizophrenia. Biological 
Psychiatry 70:636-645. 
Neddens J, Fish KN, Tricoire L, Vullhorst D, Shamir A, Chung W, et al (2011b): 
Conserved interneuron-specific ErbB4 expression in frontal cortex of rodents, 
monkeys, and humans: implications for schizophrenia. Biological Psychiatry 
70:636-645. 
Neddens J, Vullhorst D, Buonanno A (2009): Neuregulin links dopaminergic and 
glutamatergic neurotransmission to control hippocampal synaptic plasticity. 
Communicative & Integrative Biology 2:261-264. 
Nicodemus KK, Law AJ, Radulescu E, Luna A, Kolachana B, Vakkalanka R, et al 
(2010): Biological validation of increased schizophrenia risk with NRG1, 
ERBB4, and AKT1 epistasis via functional neuroimaging in healthy controls. 
Arch Gen Psychiatry 67:991-1001. 
Nicodemus KK, Luna A, Vakkalanka R, Goldberg T, Egan M, Straub RE, 
Weinberger DR (2006): Further evidence for association between ErbB4 and 
schizophrenia and influence on cognitive intermediate phenotypes in healthy 
controls. Mol Psychiatry 11:1062-1065. 
O'Tuathaigh CM, Babovic D, O'Sullivan GJ, Clifford JJ, Tighe O, Croke DT, et al 
(2007): Phenotypic characterization of spatial cognition and social behavior in 




O'Tuathaigh CM, O'Sullivan GJ, Kinsella A, Harvey RP, Tighe O, Croke DT, 
Waddington JL (2006): Sexually dimorphic changes in the exploratory and 
habituation profiles of heterozygous neuregulin-1 knockout mice. Neuroreport 
17:79-83. 
O'Tuathaigh CMP, Harte M, O'Leary C, O'Sullivan GJ, Blau C, Lai D, et al (2010): 
Schizophrenia-related endophenotypes in heterozygous neuregulin-1 'knockout' 
mice. Eur J Neurosci 31:349-358. 
O'Tuathaigh CMP, O'Connor A-M, O'Sullivan GJ, Lai D, Harvey R, Croke DT, 
Waddington JL (2008): Disruption to social dyadic interactions but not 
emotional/anxiety-related behaviour in mice with heterozygous 'knockout' of the 
schizophrenia risk gene neuregulin-1. Prog Neuropsychopharmacol Biol 
Psychiatry 32:462-466. 
Pan B, Huang X-F, Deng C (2011): Antipsychotic treatment and neuregulin 1-ErbB4 
signalling in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 
35:924-930. 
Parlapani E, Schmitt A, Wirths O, Bauer M, Sommer C, Rueb U, et al (2010): Gene 
expression of neuregulin-1 isoforms in different brain regions of elderly 
schizophrenia patients. World J Biol Psychiatry 11:243-250. 
Petryshen TL, Middleton FA, Kirby A, Aldinger KA, Purcell S, Tahl AR, et al 
(2005): Support for involvement of neuregulin 1 in schizophrenia 
pathophysiology. Mol Psychiatry 10:366-374, 328. 
Pinkas-Kramarski R, Shelly M, Glathe S, Ratzkin BJ, Yarden Y (1996): Neu 
differentiation factor/neuregulin isoforms activate distinct receptor 
combinations. The Journal of biological chemistry 271:19029-19032. 
Pitcher GM, Kalia LV, Ng D, Goodfellow NM, Yee KT, Lambe EK, Salter MW 
(2011): Schizophrenia susceptibility pathway neuregulin 1-ErbB4 suppresses 
Src upregulation of NMDA receptors. Nat Med 17:470-478. 
Rethelyi JM, Bakker SC, Polgar P, Czobor P, Strengman E, Pasztor PI, et al (2010): 
Association study of NRG1, DTNBP1, RGS4, G72/G30, and PIP5K2A with 
schizophrenia and symptom severity in a Hungarian sample. Am J Med Genet B 
Neuropsychiatr Genet 153B:792-801. 
Rico B, Marin O (2011): Neuregulin signaling, cortical circuitry development and 
schizophrenia. Current Opinion in Genetics & Development 21:262-270. 
Rieff HI, Corfas G (2006): ErbB receptor signalling regulates dendrite formation in 
mouse cerebellar granule cells in vivo. Eur J Neurosci 23:2225-2229. 
Rieff HI, Raetzman LT, Sapp DW, Yeh HH, Siegel RE, Corfas G (1999): Neuregulin 
induces GABA(A) receptor subunit expression and neurite outgrowth in 
cerebellar granule cells. J Neurosci 19:10757-10766. 
Rimer M, Barrett DW, Maldonado MA, Vock VM, Gonzalez-Lima F (2005): 
Neuregulin-1 immunoglobulin-like domain mutant mice: clozapine sensitivity 
and impaired latent inhibition. Neuroreport 16:271-275. 
Rio C, Rieff HI, Qi P, Khurana TS, Corfas G (1997): Neuregulin and erbB receptors 
play a critical role in neuronal migration. Neuron 19:39-50. 
Role LW, Talmage DA (2007): Neurobiology: New order for thought disorders. 
Nature 448:263-265. 
Rösler TW, Depboylu C, Arias-Carrión O, Wozny W, Carlsson T, Höllerhage M, et al 
(2011): Biodistribution and brain permeability of the extracellular domain of 
neuregulin-1-β1. Neuropharmacology 61:1413-1418. 




Roussos P, Giakoumaki SG, Adamaki E, Bitsios P (2011): The influence of 
schizophrenia-related neuregulin-1 polymorphisms on sensorimotor gating in 
healthy males. Biological Psychiatry 69:479-486. 
Roy K, Murtie JC, El-Khodor BF, Edgar N, Sardi SP, Hooks BM, et al (2007): Loss 
of erbB signaling in oligodendrocytes alters myelin and dopaminergic function, 
a potential mechanism for neuropsychiatric disorders. Proceedings of the 
National Academy of Sciences of the United States of America 104:8131-8136. 
Savonenko AV, Melnikova T, Laird FM, Stewart KA, Price DL, Wong PC (2008): 
Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like 
phenotypes in BACE1-null mice. Proc Natl Acad Sci U S A 105:5585-5590. 
Schmitt A, Koschel J, Zink M, Bauer M, Sommer C, Frank J, et al (2010): Gene 
expression of NMDA receptor subunits in the cerebellum of elderly patients 
with schizophrenia. European archives of psychiatry and clinical neuroscience 
260:101-111. 
Schmucker J, Ader M, Brockschnieder D, Brodarac A, Bartsch U, Riethmacher D 
(2003): erbB3 is dispensable for oligodendrocyte development in vitro and in 
vivo. Glia 44:67-75. 
Shamir A, Kwon O-B, Karavanova I, Vullhorst D, Leiva-Salcedo E, Janssen MJ, 
Buonanno A (2012): The importance of the NRG-1/ErbB4 pathway for synaptic 
plasticity and behaviors associated with psychiatric disorders. J Neurosci 
32:2988-2997. 
Shi F, Telesco SE, Liu Y, Radhakrishnan R, Lemmon MA (2010): ErbB3/HER3 
intracellular domain is competent to bind ATP and catalyze 
autophosphorylation. Proceedings of the National Academy of Sciences of the 
United States of America 107:7692-7697. 
Shibuya M, Komi E, Wang R, Kato T, Watanabe Y, Sakai M, et al (2010): 
Measurement and comparison of serum neuregulin 1 immunoreactivity in 
control subjects and patients with schizophrenia: an influence of its genetic 
polymorphism. J Neural Transm Suppl 117:887-895. 
Shiota S, Tochigi M, Shimada H, Ohashi J, Kasai K, Kato N, et al (2008): Association 
and interaction analyses of NRG1 and ERBB4 genes with schizophrenia in a 
Japanese population. J Hum Genet 53:929-935. 
Silberberg G, Darvasi A, Pinkas-Kramarski R, Navon R (2006): The involvement of 
ErbB4 with schizophrenia: association and expression studies. Am J Med Genet 
B Neuropsychiatr Genet 141B:142-148. 
Squassina A, Piccardi P, Del Zompo M, Rossi A, Vita A, Pini S, et al (2010): NRG1 
and BDNF genes in schizophrenia: an association study in an Italian case-
control sample. Psychiatry Research 176:82-84. 
Stefansson H, Sarginson J, Kong A, Yates P, Steinthorsdottir V, Gudfinnsson E 
(2003): Association of neuregulin 1 with schizophrenia confirmed in a Scottish 
population. The American Journal of Human Genetics 72:83–87. 
Stefansson H, Sigurdsson E, Steinthorsdottir V (2002): Neuregulin 1 and 
susceptibility to schizophrenia. The American Journal of Human Genetics 
71:887-892. 
Taveggia C, Zanazzi G, Petrylak A, Yano H, Rosenbluth J, Einheber S, et al (2005): 
Neuregulin-1 type III determines the ensheathment fate of axons. Neuron 
47:681-694. 
Taylor SB, Markham JA, Taylor AR, Kanaskie BZ, Koenig JI (2011): Sex-specific 
neuroendocrine and behavioral phenotypes in hypomorphic Type II Neuregulin 
1 rats. Behav Brain Res 224:223-232. 
24 
 
Thompson M, Lauderdale S, Webster MJ, Chong VZ, McClintock B, Saunders R, 
Weickert CS (2007): Widespread expression of ErbB2, ErbB3 and ErbB4 in 
non-human primate brain. Brain Research 1139:95-109. 
Ting AK, Chen Y, Wen L, Yin D-M, Shen C, Tao Y, et al (2011): Neuregulin 1 
Promotes Excitatory Synapse Development and Function in GABAergic 
Interneurons. The Journal of Neuroscience 31:15-25. 
Tseng KY, Chambers RA, Lipska BK (2009): The neonatal ventral hippocampal 
lesion as a heuristic neurodevelopmental model of schizophrenia. Behav Brain 
Res 204:295-305. 
Tzahar E, Levkowitz G, Karunagaran D, Yi L, Peles E, Lavi S, et al (1994): ErbB-3 
and ErbB-4 function as the respective low and high affinity receptors of all Neu 
differentiation factor/heregulin isoforms. The Journal of biological chemistry 
269:25226-25233. 
van den Buuse M, Wischhof L, Lee RX, Martin S, Karl T (2009): Neuregulin 1 
hypomorphic mutant mice: enhanced baseline locomotor activity but normal 
psychotropic drug-induced hyperlocomotion and prepulse inhibition regulation. 
International Journal of Neuropsychopharmacology 29:1-11. 
Vohora D (2007): Atypical antipsychotic drugs: current issues of safety and efficacy 
in the management of schizophrenia. Curr Opin Investig Drugs 8:531-538. 
Vullhorst D, Neddens J, Karavanova I, Tricoire L, Petralia RS, McBain CJ, Buonanno 
A (2009): Selective expression of ErbB4 in interneurons, but not pyramidal 
cells, of the rodent hippocampus. J Neurosci 29:12255-12264. 
Wakatsuki S, Kurisaki T, Sehara-Fujisawa A (2004): Lipid rafts identified as 
locations of ectodomain shedding mediated by Meltrin β/ADAM19. Journal of 
Neurochemistry 89:119-123. 
Wang X-D, Su Y-A, Guo C-M, Yang Y, Si T-M (2008): Chronic antipsychotic drug 
administration alters the expression of neuregulin 1beta, ErbB2, ErbB3, and 
ErbB4 in the rat prefrontal cortex and hippocampus. International Journal of 
Neuropsychopharmacology 11:553-561. 
Wen D, Suggs SV, Karunagaran D, Liu N, Cupples RL, Luo Y, et al (1994): 
Structural and functional aspects of the multiplicity of Neu differentiation 
factors. Molecular and cellular biology 14:1909-1919. 
Wen L, Lu Y-S, Zhu X-H, Li X-M, Woo R-S, Chen Y-J, et al (2010): Neuregulin 1 
regulates pyramidal neuron activity via ErbB4 in parvalbumin-positive 
interneurons. Proceedings of the National Academy of Sciences of the United 
States of America 107:1211-1216. 
Willem M, Garratt AN, Novak B, Citron M, Kaufmann S, Rittger A, et al (2006): 
Control of Peripheral Nerve Myelination by the {beta}-Secretase BACE1. 
Science (New York, NY) 314:664-666. 
Williams N, Preece A, Spurlock G, Norton N, Williams H, Zammit S (2003): Support 
for genetic variation in neuregulin 1 and susceptibility to schizophrenia. 
Molecular Psychiatry 8:485–487. 
Woo R-S, Li X-M, Tao Y, Carpenter-Hyland E, Huang YZ, Weber J, et al (2007): 
Neuregulin-1 Enhances Depolarization-Induced GABA Release. Neuron 
54:599-610. 
Woo T-UW, Kim AM, Viscidi E (2008): Disease-specific alterations in glutamatergic 
neurotransmission on inhibitory interneurons in the prefrontal cortex in 
schizophrenia. Brain Research 1218:267-277. 
Woo T-UW, Walsh JP, Benes FM (2004): Density of glutamic acid decarboxylase 67 
messenger RNA-containing neurons that express the N-methyl-D-aspartate 
25 
 
receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and 
bipolar disorder. Arch Gen Psychiatry 61:649-657. 
Xu Z, Croslan DR, Harris AE, Ford GD, Ford BD (2006): Extended therapeutic 
window and functional recovery after intraarterial administration of neuregulin-
1 after focal ischemic stroke.[Erratum appears in J Cereb Blood Flow Metab. 
2008 Sep;28(9):1643 Note: Dosage error in article text]. J Cereb Blood Flow 
Metab 26:527-535. 
Xu Z, Jiang J, Ford G, Ford BD (2004): Neuregulin-1 is neuroprotective and 
attenuates inflammatory responses induced by ischemic stroke. Biochemical and 
Biophysical Research Communications 322:440-446. 
Yamamori H, Hashimoto R, Verrall L, Yasuda Y, Ohi K, Fukumoto M, et al (2011): 
Dysbindin-1 and NRG-1 gene expression in immortalized lymphocytes from 
patients with schizophrenia. J Hum Genet 56:478-483. 
Yang J, Si T, Ruan Y, Ling Y, Han Y, Wany X (2003): Association study of 
neuregulin 1 gene with schizophrenia. Molecular Psychiatry 8:706–709. 
Yarden Y, Sliwkowski MX (2001): Untangling the ErbB signalling network. Nature 
reviews Molecular cell biology 2:127-137. 
Yau HJ, Wang HF, Lai C, Liu FC (2003): Neural development of the neuregulin 
receptor ErbB4 in the cerebral cortex and the hippocampus: preferential 
expression by interneurons tangentially migrating from the ganglionic 
eminences. Cereb Cortex 13:252-264. 
Yokley JL, Prasad KM, Chowdari KV, Talkowski ME, Wood J, Gur RC, et al (2012): 
Genetic associations between neuregulin-1 SNPs and neurocognitive function in 
multigenerational, multiplex schizophrenia families. Psychiatr Genet 22:70-81. 
Yokozeki T, Wakatsuki S, Hatsuzawa K, Black RA, Wada I, Sehara-Fujisawa A 
(2007): Meltrin β (ADAM19) mediates ectodomain shedding of Neuregulin β1 
in the Golgi apparatus: fluorescence correlation spectroscopic observation of the 
dynamics of ectodomain shedding in living cells. Genes to Cells 12:329-343. 
Yu XM, Askalan R, Keil GJ, 2nd, Salter MW (1997): NMDA channel regulation by 
channel-associated protein tyrosine kinase Src. Science (New York, NY) 
275:674-678. 
Yurek DM, Zhang L, Fletcher-Turner A, Seroogy KB (2004): Supranigral injection of 
neuregulin1-β induces striatal dopamine overflow. Brain Research 1028:116-
119. 
Zhang H-x, Li W-q, Zhang H-s, Zhang Y, Zhao J-p, Lv L-x, Yang G (2011): 
[Expressional changes of neuregulin-1 gene mRNA in peripheral blood from 
schizophrenia patients]. Chung Hua I Hsueh I Chuan Hsueh Tsa Chih 28:620-
624. 
Zhang H-X, Zhao J-P, Lv L-X, Li W-Q, Xu L, Ouyang X, et al (2008): Explorative 
study on the expression of neuregulin-1 gene in peripheral blood of 
schizophrenia. Neuroscience Letters 438:1-5. 
Zheng Y, Watakabe A, Takada M, Kakita A, Namba H, Takahashi H, et al (2009): 
Expression of ErbB4 in substantia nigra dopamine neurons of monkeys and 















Figure 1. A schematic diagram showing the hypothetical interaction between NRG1-
ErbB4 signalling and neurotransmission systems in schizophrenia. The output of 
pyramidal neurons in the prefrontal cortex and ventral hippocampus is regulated by 
excitatory glutamatergic neurons (orange colour) and inhibitory GABAergic 
interneurons (shown in blue). Basket cells (BA) target the somata pyramidal neurons; 
chandelier cells (CH) terminate at or near the axon hillock of pyramidal neurons. 
Theses GABAergic interneurons are regulated by glutamatergic projections from 
various brain regions, including the cortex, thalamus, hippocampus and amygdala. 
Recent histological studies showed that ErbB4 receptors are located exclusively on 
PV-positive GABAergic interneurons in the frontal cortex and hippocampus (Fazzari 
et al 2010; Neddens and Buonanno 2010; Neddens et al 2011b), although an 
electrophysiological study suggested a direct effect of NRG1 on the pyramidal 
neurons (Pitcher et al 2011). NRG1 regulates NMDA receptors by activating ErbB4 
that co-localise with postsynaptic density (PSD) 95, and then inhibits Src-mediated 
enhancement of NMDA receptor function. In schizophrenia, in the case of increased 
NRG1-ErbB4 signalling (as shown in many studies that are summarized in text), it 
will cause NMDA receptor hypofunction by modulating Src activity, which may 
directly act on pyramidal neurons or indirectly through GABAergic interneurons. 
NMDA hypofunction may cause GABAergic deficits by down-regulating GAD67 
(67-kilodalton isoform of glutamic acid decarboxylase) and decreasing GABA 
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production. On the other hand, NRG1-ErbB4 signalling can activate Fyn and Pyk2 
kinases leading to increased NMDA NR2B phosphorylation. Therefore, in the case of 
hypofunctional NRG1-ErbB4 signalling, as observed in several studies in 
schizophrenia patients, it may cause decreased activation of Fyn and Pyk2 kinases and 
NMDA phosphorylation, also resulting NMDA hypofunction. In the midbrain, ErbB4 
receptors are heavily expressed on dopaminergic neurons, whereas the function of 
ErbB4 receptors in dopaminergic neurons in the midbrain is controversial. 
Hypofunction of NMDA receptors may directly affect functioning of the 
dopaminergic system (shown in green) in the midbrain, or indirectly via GABA 
interneurons (unclear, shown as question mark), causing hyperfunction of dopamine 
output to the striatum, and deficits of dopamine output to the cortex/hippocampus.  
 
